Taiwan-based GlycoNex, a biotech company focused on the development of glycan-directed cancer immunotherapies, has announced a licensing agreement for its denosumab biosimilar, SPD8.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback